Erectile dysfunction: current situation
https://doi.org/10.21518/2079-701X-2015-2-28-32
Abstract
Erectile dysfunction (ED) means inability to achieve and maintain an erection long enough to engage in sexual intercourse [1, 2]. Erectile dysfunction is an obvious cause of a decline in the overall quality of life [9]. For the implementation of erectile function in the body responsible psychological, neurovascular and endocrine factors. [1, 2] Sexual arousal causes release of relaxing neurotransmitters from nerve endings and endothelial cells of the penis resulting in the relaxation of smooth muscles of arteries and arterioles, which inevitably leads to filling with blood and expansion of corpora cavernosa. [2, 11] During erection subtunicular plexus between the trabeculae and the tunica albuginea become compressed, resulting in almost total occlusion of venous outflow. [9] During the full-erection phase, when penis is at 90 degrees perpendicular to the abdomen, intracavernous pressure reaches 90-100 mm Hg, while the blood volume in the erect penis may exceed that in the soft penis by 8 times [10, 11].
About the Authors
N. D. Akhvlediani
First Moscow State Medical University named after I.M. Sechenov, the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
S. N. Allenov
First Moscow State Medical University named after I.M. Sechenov, the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
I. P. Matyukhov
First Moscow State Medical University named after I.M. Sechenov, the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Z. S. Inoyatov
First Moscow State Medical University named after I.M. Sechenov, the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Costa P. Erectile dysfunction: knowledge, wishes and attitudes. Results of a French study of 5099 men aged 17 to 70. P. Costa, Avances, L. Prog. Urol., 2003, 13: 85-91.
2. McVary KT. Erectile dysfunction. New Engl. J. Med., 2007, 357: 2472-81.
3. Vardi Y, Bulus M, Reisner S et al. Effects of sildenafil citrate (Viagra) on hemodynamic parameters during exercise testing and occurrence of ventricular arrhythmias in patients with erectile dysfunction and cardiovascular disease. European Urology, 2003, 43: 544-51.
4. Feldman HA., Goldstein I, Hatzichristou DG et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J. Urology, 1994, 151: 54-61.
5. Гамидов С.И. Исследование эндотелиальной функции кавернозных артерий в диагностике артериогенной эректильной дисфункции. С.И. Гамидов, В.В. Иремашвили. Андрология и гени-тальная хирургия, 2006, 4: 25-30.
6. Глыбочко П.В., Аляев Ю.Г., Есилевский Ю.М. и соавт. Выбор препаратов ингибиторов фос-фодиэстеразы 5-го типа для лечения больных эректильной дисфункцией и хроническим простатитом. Сеченовский вестник, 2013, 2: 33-40.
7. Briganti A, Gallina A, Suardi N, Capitanio U, Tutolo M, Bianchi M, Passoni N, Salonia A, Colombo R, Di Girolamo V, Guazzoni G, Rigatti P Montorsi P. Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: A proposal of a novel preoperative risk stratification. J Sex Med, 2010, 7: 2521-31.
8. Feneley MR, Carruthers M. Is testosterone treatment good for the prostate? Study of safety during long-term treatment. J Sex Med., 2012, 9: 2138-49.
9. Локшин К.Л. Сравнительная характеристика силденафила и других ингибиторов фосфо-диэстеразы 5-го типа в лечении больных эрек-тильной дисфункцией (обзор литературы). Русский медицинский журнал, 2013, 18: 936-939.
10. Вагнер Г., Грин Р. Импотенция. Физиология, психология, хирургия, диагностика и лечение. Пер. с англ. М.: Медицина, 1985: 240.
11. Beutel ME. Epidemiology of sexual dysfunction in the male population. M.E. Beutel, W. Weidner, E. Brahler. Andrologia, 2006, 38(4): 115-121.
12. Mann K, Pankok J, Connemann B et al. Sleep investigations in erectile dysfunction. J. Psychiatr. Res., 2005, 39: 93-9.
13. Reffelmann T, Kloner RA. Therapeutic Potential of Phosphodiesterase 5 Inhibition for Cardiovascular Disease. Circulation, 2003, 15: 239-44.
14. Diabetes and sexual function in older adults: results of an international survey / A. Nicolosi [etal.] // Br. J. Diabetes Vase. Dis., 2002, 2: 336339.
15. Seftel AD. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. A.D. Seftel, P. Sun, R. Swindle. J. Urol. (Baltimore), 2004, 171(6): 2341-2345.
16. Berthet J, Sutherland EW, Rall TW. The assay of glucagon and epinephrine with use of liver homogenates. J. Biol. Chem., 1957, 229(1): 351-61.
17. Desouza C, Akers D, Parulkar A, Fonseca VA, Lumpkin D. Acute and prolonged effects of sildenafil on brachial artery flow mediated dilatation in type 2 diabetes. Diabetes Care, 2002, 25(8): 336-9.
18. Lee AJ, Chiao TB, Tsang MP. Sildenafil for Pulmonary Hypertension. Ann Pharmacother, 2005, 39(5): 869-84.
19. Rosengarten B, Schermuly RT, Voswinckel R et al. Sildenafil improves dynamic vascu-lar function in the brain: studies in patients with pulmonary hypertension. Cerebrovasc Dis., 2006, 21(3): 194-200.
20. Chua R, Keogh A, Miyashita M. Novel use of sildenafil in the treatment of portopulmon-ary hypertension. J Heart Lung Transplant, 2005, 24(4): 498-500.
Review
For citations:
Akhvlediani ND, Allenov SN, Matyukhov IP, Inoyatov ZS. Erectile dysfunction: current situation. Meditsinskiy sovet = Medical Council. 2015;(2):28-32. (In Russ.) https://doi.org/10.21518/2079-701X-2015-2-28-32
Views:
720
Email this article 